Advanced search    

Search: authors:"Paul Aisen"

13 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

Background Treatment of mild-moderate Alzheimer’s disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores. Methods For this retrospective study, we examined banked CSF and plasma samples from a subset of AD subjects with CSF A...

Early Indications of Future Cognitive Decline: Stable versus Declining Controls

This study aimed to identify baseline features of normal subjects that are associated with subsequent cognitive decline. Publicly available data from the Alzheimer’s Disease Neuroimaging Initiative was used to find differences in baseline clinical assessments (ADAScog, AVLT, FAQ) between cognitively healthy individuals who will suffer cognitive decline within 48 months and those...

Alzheimer’s disease progression by geographical region in a clinical trial setting

Introduction To facilitate enrollment and meet local registration requirements, sponsors have increasingly implemented multi-national Alzheimer’s disease (AD) studies. Geographic regions vary on many dimensions that may affect disease progression or its measurement. To aid researchers designing and implementing Phase 3 AD trials, we assessed disease progression across geographic...

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

Introduction Most Alzheimer’s disease (AD) clinical trials enroll participants multinationally. Yet, few data exist to guide investigators and sponsors regarding the types of patients enrolled in these studies and whether participant characteristics vary by region. Methods We used data derived from four multinational phase III trials in mild to moderate AD to examine whether...

CSF Biomarker and PIB-PET–Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects

Beta-amyloid (Aβ) is a histopathological hallmark of Alzheimer’s disease dementia, but high levels of Aβ in the brain can also be found in a substantial proportion of nondemented subjects. Here we investigated which 2-year rate of brain and cognitive changes are present in nondemented subjects with high and low Aβ levels, as assessed with cerebrospinal fluid and molecular...

Large-scale genomics unveil polygenic architecture of human cortical surface area

Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway.Srdjan DjurovicUC San Diego, La Jolla, CA 92093, USA.Connor McCabe, Erik Newman, Mark Appelbaum, Anthony Gamst, Paul Aisen, Ronald G. Thomas ... , Sarah Murray, Cinnamon Bloss, Mark Appelbaum, Anthony Gamst, Wesley Thompson & Hauke BartschAlzheimer’s Disease Neuroimaging InitiativeMichael Weiner, Paul Aisen, Ronald Petersen, Clifford R. Jack Jr

Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease

FargherConsortiaThe Alzheimer’s Disease Neuroimaging InitiativeMichael W. Weiner, Paul Aisen, Ronald Petersen, Clifford R. Jack Jr., William Jagust, John Q. Trojanowki, Arthur W. Toga, Laurel Beckett, Robert C. Green

Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns

Accumulating evidence suggests that Alzheimer’s disease (AD) is heterogenous and can be classified into several subtypes. Here, we propose a robust subtyping method for AD based on cortical atrophy patterns and graph theory. We calculated similarities between subjects in their atrophy patterns throughout the whole brain, and clustered subjects with similar atrophy patterns using...

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology

. FurstConsortiaThe Alzheimer's Disease Neuroimaging InitiativeMichael W. Weiner, Paul Aisen, Ronald Petersen, Clifford R. Jack, William Jagust, John Q. Trojanowki, Arthur W. Toga, Laurel Beckett, Robert C. Green

Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts

The Clusterin (CLU) gene, also known as apolipoprotein J (ApoJ), is currently the third most associated late-onset Alzheimer’s disease (LOAD) risk gene. However, little was known about the possible effect of CLU genetic variants on AD pathology in brain. Here, we evaluated the interaction between 7 CLU SNPs (covering 95% of genetic variations) and the role of CLU in β-amyloid (A...

Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

FriedlStanford University, Stanford, California, USAJerome A. Yesavage, Joy L. Taylor & Ansgar J. FurstConsortiaThe Alzheimer’s Disease Neuroimaging InitiativeMichael W. Weiner, Paul Aisen, Ronald Petersen

Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits

Gessert, James Brewer, Helen Vanderswag, Tamie Sather, Gus Jiminez, Archana B. Balasubramanian, Jennifer Mason, Iris Sim, Paul Aisen, Melissa Davis, Rosemary Morrison, Danielle Harvey, Lean Thal & Laurel ... Bartzokis, Paul Thompson, Michael Donohue, Ronald G. Thomas, Sarah Walter, Devon Gessert, James Brewer, Helen Vanderswag, Tamie Sather, Gus Jiminez, Archana B. Balasubramanian, Jennifer Mason, Iris Sim, Paul

Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE

 & Balebail Ashok RajDepartment of DefenceKarl FriedlStanford UniversityJerome A. Yesavage, Joy L. Taylor & Ansgar J. FurstConsortiaAlzheimer's Disease Neuroimaging InitiativeMichael W. Weiner, Paul Aisen